Moving beyond guidelines: Are report cards the answer to high rates of uncontrolled hypertension?

Current Hypertension Reports

Volumn 8, Issue 4, 2006, Pages 324-329

  Ruzicka, Marcel ^b   Leenen, Frans H H ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DISEASE CONTROL; DISEASE SEVERITY; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; PATIENT ATTITUDE; PATIENT MONITORING; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DRUG PRESCRIPTIONS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTIONS, DRUG; PREVALENCE; RISK FACTORS;

EID: 33747626359     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0072-1     Document Type: Review

References (40)

1. Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003, 290:199-206.
2. Prospective Studies Collaboration: Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual date for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
3. Hsu C, McCulloch CE, Darbinian J, et al.: Elevated BP and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005, 165:923-928.
4. Lloyd-Jones DM, Evans JC, Levy D: Hypertension in adults across the age spectrum. JAMA 2005, 294:466-472.
5. Staessen JA, Gasowski J, Wang JG, et al.: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000, 355:865-872.
6. Staessen JA, Wang JG, Thijs L: Cardiovascular protection and BP reduction: a meta-analysis. Lancet 2001, 358:1305-1315.
7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
8. Muscha Steckelings U, Stoppelhaar M, Sharma AM, et al.: and the Hydra Study Group: HYDRA: Possible determinants of unsatisfactory hypertension control in German primary care patients. Blood Pressure 2004, 13:80-88.
9. Roux O, Chapellier M, Czernichow S, et al.: Determinants of hypertension control in a large French population of treated hypertensive subjects. Blood Pressure 2006, 15:6-13.
10. Psaltopoulou T, Orfanos P, Naska A, et al.: Prevalence, awareness, treatment and control of hypertension in a general population sample of 26,913 adults in the Greek EPIC study. Int J Epidemiol 2004, 33:1345-1352.
11. Cifkova R, Skodova Z, Lanska V, et al.: Prevalence, awareness, treatment, and control of hypertension in the Czech Republic. Results of two nationwide cross-sectional surveys in 1997/1998 and 2000/2001, Czech Post-MONICA Study. J Hum Hypertens 2004, 18:571-579.
12. Zdrojewski T, Szpakowski P, Bandosz P, et al.: Arterial hypertension in Poland in 2002. J Hum Hypertens 2004, 18:557-562.
13. Lim TO, Morad Z, Group HS: Prevalence, awareness, treatment and control of hypertension in the Malaysian adult population: results from the national health and morbidity survey 1996. Singapore Med J 2004, 45:20-27.
14. Wang TJ, Vasan RS: Epidemiology of uncontrolled hypertension in the United States. Circulation 2005, 112:1651-1662.
15. Ruzicka M, Leenen FHH: Combination therapy as first-line treatment of arterial hypertension. Can J Cardiol 2002, 18:1317-1327.
16. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial: HOT Study Group. Lancet 1998, 351:1755-1762.
17. Canzanello VJ, Jensen PL, Schwartz LL, et al.: Improved BP control with a physician-nurse team and home BP measurement. Mayo Clin Proc 2005, 80:31-36.
18. Garg JP, Elliott WJ, Folker A, et al.: Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005:18:619-626.
19. Steinman MA, Fischer MA, Shlipak MG, et al.: Clinician awareness of adherence to hypertensive guidelines. Am J Med 2004, 117:747-754.
20. Berlowitz DR, Ash AS, Hickey EC, et al.: Inadequate management of BP in a hypertensive population. N Engl J Med 1998, 339:1957-1963.
21. Lloyd-Jones DM, Evans JC, Larson MG, et al.: Treatment and control of hypertension in the community: a prospective analysis. Hypertension 2002, 40:640-646.
22. Okonofua EC, Simpson KN, Jesri A, et al.: Therapeutic inertia is an impediment to achieving the healthy people 2010 BP control goals. Hypertension 2006, 47:345-351.
23. Phillips LS, Branch WT, Cook CB, et al.: Clinical inertia. Ann Intern Med 2001, 135:825-834.
24. Coca A: Actual BP control: Are we doing things right? J Hypertens 1998, 16:S45-S51.
25. Mancia G, Sega R, Milesi C: BP control in the hypertensive population. Lancet 1997, 349:454-457.
26. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High BP: A cooperative study. JAMA 1977,237:255-261.
27. The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High BP. Arch Intern Med 1984, 144:1045-1057.
28. Ramsay L,Williams B, Johnston G, et al.: Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999, 13:569-592.
29. 1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liason Committee. Hypertension 1993, 22:392-403.
30. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines Subcommittee. Blood Pressure 1999:1:9-43.
31. Hyman DJ, Pavlik VN: Self-reported hypertension treatment practices among primary care physicians. BP thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000, 160:2281-2286.
32. Materson BJ, Reda DJ,Cushman WC: Single drug therapy for hypertension in men: a comparison of six antihypertensive drugs with placebo. N Engl J Med 1993, 328:914-921.
33. Morgan TO, Anderson AIE, MacInnis RJ: ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001, 14:241-247.
34. Ferrari P, Hess L, Pechere-Bertschi A, et al.: Reasons for not intensifying anti-hypertensive treatment (RIAT): a primary care anti-hypertensive study. J Hypertens 2004, 22:1221-1229.
35. Oliveria SA, Lapuerta P, McCarthy BD, et al.: Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002, 162:413-420.
36. Leenen FHH. ALLHAT: What has it taught us so far? CMAJ 2004,171:719-720.
37. Cushman WC, Ford CE, Cutler JA, et al.: for the ALLHAT Collaborative Research Group: Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002, 4:393-404.
38. Towsend RR, Shulkin DJ, Bernard D: Improved outpatient hypertension control with disease management guidelines. Am J Hypertens 1999, 12:88A.
39. Jha AK, Perlin JB, Kizer KW, et al.: Effect of the transformation of the Veterans Affairs Health Care System on the quality of care. N Eng J Med 2003, 348:2218-2227.
40. Berlowitz DR, Cushman WC, Glassman P: Hypertension in adults across age groups. JAMA 2005, 294:2970-2371.